<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lukas, JC</style></author><author><style face="normal" font="default" size="100%">Karikas, G</style></author><author><style face="normal" font="default" size="100%">Gazouli, M.</style></author><author><style face="normal" font="default" size="100%">Kalabalikis, P</style></author><author><style face="normal" font="default" size="100%">Hatzis,T.</style></author><author><style face="normal" font="default" size="100%">Macheras, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacokinetics of teicoplanin in an ICU population of children and infants</style></title><secondary-title><style face="normal" font="default" size="100%">PHARMACEUTICAL RESEARCH</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">infants</style></keyword><keyword><style  face="normal" font="default" size="100%">NONMEM</style></keyword><keyword><style  face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style  face="normal" font="default" size="100%">simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Teicoplanin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">NOV</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">11</style></number><publisher><style face="normal" font="default" size="100%">KLUWER ACADEMIC/PLENUM PUBL</style></publisher><pub-location><style face="normal" font="default" size="100%">233 SPRING ST, NEW YORK, NY 10013 USA</style></pub-location><volume><style face="normal" font="default" size="100%">21</style></volume><pages><style face="normal" font="default" size="100%">2064-2071</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">{Purpose. Better dosing is needed for antibiotics, including teicoplanin (TEI), to prevent emergence of resistant bacterial strains. Here, we assess the TEI pharmacokinetics (PK) related to a 10 mg/l minimum inhibitory concentration (MIC) target in ICU children (4 to 120 months; n=20) with gram+infections. Methods. Standard administration of TEI was with three 10 mg/kg Q12h, loading infusions, and maintainance with 10 mg/kg or 15 mg/kg Q24h. During maintenance, 9 samples (3/day) were collected per patient and the PK analyzed with Nonlinear Mixed Effects Model (NONMEM). Results. Thirty-five percent of concentrations in older children (greater than or equal to2 months) vs. 8% in younger infants (&lt;12 months) were below the target MIC. The global bicompartmental population PK parameters were {[}mean (interindividual CV%)] CL=0.23 l/h {[}72%]</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type></record></records></xml>